PD-1 Inhibitor Raises PFS in Advanced Acral Melanoma

(MedPage Today) — First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but statistically significant increase in progression-free survival (PFS) compared with treatment with dacarbazine…

Source link : https://www.medpagetoday.com/hematologyoncology/skincancer/119251

Author :

Publish date : 2026-01-02 19:17:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

PD-1 Inhibitor Raises PFS in Advanced Acral Melanoma

Fossil analysis adds to debate over how earliest known hominin walked

JFK’s Granddaughter Dies From AML; GI Cancers Expected to Double; Cancer Trials Axed

Related Posts

Cardiology Group to Pay Nearly $5 Million for Alleged Vein Ablation Fraud

U.S. Flu Season Winding Down

Low Testosterone May Raise Risk of ‘Extreme’ Prostate Cancer Progression

New U.S. Lipid Guideline Redefines Risk Categories, Boosts Non-Cholesterol Tests

Reclassification From Type 2 to Type 1 Diabetes Not Uncommon

COVID, Then Lung Cancer; Revisiting Nuclear Power and Cancer; Anti-Tumor Cherries?

Cardiology Group to Pay Nearly $5 Million for Alleged Vein Ablation Fraud

U.S. Flu Season Winding Down

Low Testosterone May Raise Risk of ‘Extreme’ Prostate Cancer Progression

New U.S. Lipid Guideline Redefines Risk Categories, Boosts Non-Cholesterol Tests

Reclassification From Type 2 to Type 1 Diabetes Not Uncommon

COVID, Then Lung Cancer; Revisiting Nuclear Power and Cancer; Anti-Tumor Cherries?

Adapting Communication for Different CLL Patients

Drugs Compared for Steroid-Linked Osteoporosis: What’s Best?

Categories

Archives